Comparative Pharmacology
Head-to-head clinical analysis: DAPSONE versus TRIVAGIZOLE 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAPSONE versus TRIVAGIZOLE 3.
DAPSONE vs TRIVAGIZOLE 3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dapsone is a sulfone antibiotic that inhibits bacterial synthesis of dihydrofolic acid via competition with para-aminobenzoic acid for the active site of dihydropteroate synthase. It also has anti-inflammatory and immunomodulatory properties, including inhibition of neutrophil myeloperoxidase and suppression of neutrophil chemotaxis.
Terconazole is an imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and fungal cell membrane integrity.
100 mg orally once daily for leprosy or dermatitis herpetiformis.
One vaginal tablet (200 mg) inserted intravaginally at bedtime for 3 consecutive days.
None Documented
None Documented
Clinical Note
moderateDapsone + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Dapsone."
Clinical Note
moderateDapsone + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Dapsone."
Clinical Note
moderateDapsone + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Dapsone."
Clinical Note
moderateDapsone + Erythromycin
Terminal elimination half-life is 20-30 hours (mean 28 hours). In patients with renal impairment, half-life may be prolonged up to 48 hours.
Terminal elimination half-life is approximately 7-9 hours in healthy adults, allowing for twice-daily dosing. In patients with hepatic impairment, half-life may be prolonged up to 18 hours, requiring dose adjustment.
Primarily renal (70-85% as metabolites, <20% unchanged). Biliary/fecal excretion accounts for 10-15%.
Renal excretion accounts for approximately 70-80% of the administered dose, with about 20% excreted as unchanged drug and the remainder as metabolites. Fecal excretion is minimal (<5%).
Category C
Category C
Antibacterial
Antibacterial/Antifungal Combination
"The metabolism of Erythromycin can be decreased when combined with Dapsone."